Description
UrgoClean Ag is an innovative, absorbent and gelling non-woven dressing, consisting of poly-absorbent polyacrylate fibres that ensure complete cleansing and debridement (of slough, fibrin, exudate, bacterial and biofilm residues) and a TLC-Ag lipido-colloidal matrix that provides antimicrobial action. The combined action of the TLC-Ag matrix and the poly-absorbent fibres allows for an antimicrobial, anti-biofilm and complete cleansing action.
- The TLC-Ag matrix of UrgoClean Ag gels on contact with the wound exudate, reducing the bacterial load of the lesion with a rapid and broad-spectrum action (tested on 36 bacterial strains and 4 yeasts, including antibiotic-resistant bacterial strains - MRSA, ERV, ESBL).
- On contact with the lesion, the poly-absorbent fibres of UrgoClean Ag gel and break down the biofilm matrix, allowing silver ions to exert their bactericidal action within the biofilm. The combined action of the poly-absorbent fibres and the TLC-Ag matrix has been shown to effectively reduce the concentration of sessile MRSA and P. aeruginosa bacteria within 24 hours and for 7 days (biofilm reduction > 99.99%). The anti-biofilm action of UrgoClean Ag is superior to Idrofibra Ag+Extra and to DACC dressings.
- UrgoClean Ag removes all factors that promote bacterial proliferation and that can limit the action of silver. The poly-absorbent fibres of UrgoClean Ag absorb and trap slough, exudate and biofilm residues through an electrostatic mechanism. UrgoClean Ag has clinically shown after 4 weeks of treatment to reduce slough by 62.5% and to cleanse 59% of lesions (cleansed lesion = lesion covered with less than 30% slough).
- The dressing is removed in one piece thanks to the acrylic core present in the poly-absorbent fibres.
- UrgoClean Ag ensures atraumatic and pain-free care thanks to the moist environment provided by the TLC-Ag3 matrix.
- UrgoClean manages minor bleeding due to its hemostatic properties.
- UrgoClean Ag is trimmable and can be used with a secondary dressing.
- UrgoClean Ag can be combined with compression therapy, when prescribed.

Composition
Antimicrobial dressing composed entirely of poly-absorbent polyacrylate fibres, cleansing and gelling, and a micro-adherent lipido-colloidal TLC-Ag matrix (TLC-Ag: Lipido-Colloidal Technology, composed of carboxymethylcellulose particles, lipid substances and silver salts) to combat local infection through a combined antimicrobial/anti-biofilm and complete cleansing action. UrgoClean Ag has the ability to cleanse and keep the lesion clean.

How to use
Cleanse the wound using the conventional care protocol, then rinse with saline solution. If an antiseptic has been used previously, thoroughly rinse the wound with saline solution before applying UrgoClean Ag. The use of UrgoClean Ag does not preclude the need for mechanical debridement, if necessary. Remove the protective tabs and apply the micro-adherent part of UrgoClean Ag in contact with the wound and perilesional skin. If necessary, UrgoClean Ag can be cut with sterile scissors to adapt the size of the dressing to that of the wound. It is recommended to use a bandage to secure the dressing and ensure it remains in place. Furthermore, it is possible to cover UrgoClean Ag with a secondary dressing suitable for the location of the wound and the degree of exudation. If prescribed, apply compression therapy. The UrgoClean Ag dressing should be changed every 1-2 days at the beginning of treatment, and subsequently when necessary (up to 7 days) depending on the amount of exudate and the clinical state of the wound. Treatment with Urgoclean Ag should not last longer than one month.
The micro-adherent TLC-Ag matrix present in UrgoClean Ag can adhere to latex surgical gloves. Therefore, it is advisable to moisten the gloves with normal saline solution to handle the dressing more easily. During the debridement process, the lesion may appear larger than usual. This is due to the effective removal of slough.

Warnings
Contraindicated in cases of known sensitivity to silver.
UrgoClean Ag is not recommended for use as a surgical sponge for highly exuding wounds.
Do not use UrgoClean Ag in combination with hydrogen peroxide, organo-mercury-based antiseptics or antiseptics containing hexamidine.
Do not use on patients undergoing Open Magnetic Resonance Imaging (MRI).
Treatment with UrgoClean Ag should be carried out under medical supervision.
The use of UrgoClean Ag does not exempt the need for systemic antibacterial treatment for infection, in line with the local protocol.
Concomitant use with other local treatments is not recommended.
Avoid contact with electrodes or conductive gels used in case of EEG or ECG.
Healthcare personnel should be informed of the scarce information and specific data on the prolonged and repeated use of silver dressings, especially in children and infants.
In the absence of specific clinical data, use in pregnant or breastfeeding women is not recommended.
Individual sterile packaging, single-use only: reuse of a single-use package may pose risks of infection.
Do not re-sterilize the dressing.
Before use, ensure that the sterile protective film is intact. Do not use if the packaging is damaged.

Storage
Store at room temperature away from light and heat sources.
Shelf life unopened: 36 months.

Format
Available in:
-pack of 5 pieces, size: 6 cm x 6 cm;
-pack of 5 pieces, size: 10 cm x 10 cm;
-pack of 5 pieces, size: 15 cm x 15 cm;
-pack of 10 pieces, size: 6 cm x 6 cm;
-pack of 10 pieces, size: 10 cm x 10 cm;
-pack of 10 pieces, size: 15 cm x 15 cm.

Code 552093, 552273, 552095, 552094, 552274, 551749

Bibliography
Lazareth I., et al., The Role of a Silver Releasing Lipido-colloid Contact Layer in Venous Leg Ulcers Presenting Inflammatory Signs Suggesting Heavy Bacterial Colonization: Results of a Randomized Controlled Study. WOUNDS 2008;20 (6):158–166.
Meaume S., et al., Evaluation of two fibrous wound dressings for the management of leg ulcers: Results of a European randomised controlled trial (EARTH RCT). J Wound Care, Vol 23, No 3, March 2014, 105-116.
Dalac S., et al., Clinical evaluation of a dressing with poly absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non-comparative trial. J Wound Care, Vol 25, No 9, September 2016.
J. Dissemond, Results of a national multicentre observational trial on desloughing properties on wounds at risk or with signs of a local infection with a polyabsorbent dressing with silver. Oral communication. EWMA 2017.
Desroche N. et al., Characterization of the antimicrobial spectrum and anti-biofilm activity of a new silver-containing dressing with poly-absorbent fibres and antimicrobial silver matrix. Poster EWMA May 2016.
Desroche N., et al., Antibacterial properties and reduction of MRSA biofilm with a dressing combining poly-absorbent fibres and a silver matrix. J Wound Care, Vol 25, No 10, October 2016.
Percival SL. Restoring balance: biofilms and wound dressings. J Wound Care. 2018 Feb;27(2): 102-13.
Desroche N. et al, Evaluation of in vitro anti-biofilm activities of two dressings with poly-absorbent dressing fibres and a DACC-coated dressing. Poster EWMA 2017.
UrgoClean Ag data on file.
Pernot JM, et al., Interactions between poly-absorbent fibres and fibrin. Poster Journées Cicatrisations. January 2017.
Percival SL, et al. Slough and biofilm: removal of barriers to wound healing by desloughing. J Wound Care. 2015 Nov;24 (11):498,500-3,506-10.